To evaluate improvement in best-corrected visual acuity (BCVA) and the reduction of central retinal thickness (CRT) in patients with macular edema secondary to retinal vein occlusion (RVO) after intravitreal bevacizumab (IVB) injection combined with macular grid photocoagulation.
Methods
A retrospective study of 54 consecutive eyes with macular edema associated with RVO. The BCVA and CRT, recorded with spectral-domain optical coherence tomography, were evaluated at baseline and 1, 3, 6, and 12 months after treatment onset. Intravitreal bevacizumab injection was administered at baseline, and macular grid photocoagulation 15 days later. During follow-up, additional IVB, at 1-month intervals, was administered if persistent or recurrent macular edema was observed on optical coherence tomography.
Results
Best-corrected visual acuity was improved and CRT was reduced at 1, 3, 6, and 12 months of follow-up. Compared with initial values, the final CRT was significantly reduced in patients with branch RVO (35 patients) and in patients with central RVO (19 patients) (p<0.05). Also, BCVA was significantly improved in both groups of patients (p<0.05).
Conclusions
Intravitreal bevacizumab injection combined with macular grid photocoagulation reduces recurrent macular edema associated with branch RVO and central RVO.
WongTYScottIUClinical practice. Retinal-vein occlusion. N Engl J Med20103632135–44
5.
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol198498271–82
6.
Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol198610434–41
7.
HayrehSSRubensteinLPodhajskyPArgon laser scatter photocoagulation in treatment of branch retinal vein occlusion. A prospective clinical trial. Ophthalmologica19932061–14
8.
Battaglia ParodiMSavianoSRavalicoGGrid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol19992371024–7
9.
ParodiMBSpasseSIaconoPDi StefanoGCanzianiTRavalicoGSubthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology20061132237–42
10.
ParodiMBCentral vein occlusion and laser treatment. Arch Ophthalmol1995113555
11.
The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology19951021425–33
12.
The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol1997115486–91
13.
CekiçOChangSTsengJJIntravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina200525851–5
14.
LeeHShahGKIntravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina200525551–5
15.
KreplerKErgunESacuSIntravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand200583600–4
16.
PathaiSIntravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye200721255–6
17.
CakirMDoganMBayraktarZEfficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina200828465–72
18.
IpMSScottIUVanVeldhuisenPCSCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol20091271101–14
19.
ScottIUIpMSVanVeldhuisenPCSCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol20091271115–28
20.
HallerJADugelPWeinbergDVChouCWhitcupSMEvaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina20092946–51
21.
MansoorSKuppermannBDKenneyMCIntraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res200926770–84
22.
HallerJABandelloFBelfortRJrOZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology20101171134–46
23.
InataniMIwaoKKawajiTIntraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol2008145676–81
24.
HiranoYItoTNozakiMIntraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol200953519–22
25.
Di AntonioLTotoLCarpinetoPMastropasquaADe NicolaCMastropasquaLMacular pseudohole development after sustained-release dexamethasone intravitreal implant for macular edema due to central retinal vein occlusion. Eur J Ophthalmol201424134–7
26.
AielloLPAveryRLArriggPGVascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med19943311480–7
27.
RabenaMDPieramiciDJCastellarinAANasirMAAveryRLIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina200727419–25
28.
KriechbaumKMichelsSPragerFIntravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol200892518–22
29.
JaissleGBZiemssenFPetermeierK[Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]Ophthalmologe2006103471–5
30.
FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov20043391–400
31.
DemirMObaEGulkilikGOdabasiMOzdalEIntravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. Clin Ophthalmol20115745–9
32.
AlgverePVvon WendtGGudmundssonJVisual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin). Acta Ophthalmol201088836–41
33.
GutiérrezJCBarquetLACaminalJMIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Clin Ophthalmol20082787–91
34.
MoradianSFaghihiHSadeghiBIntravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol2011249193–200
35.
HoehAEAchTSchaalKBScheuerleAFDithmarSLong-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol20092471635–41
36.
JaissleGBSzurmanPFeltgenNRetinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol2011249183–92
37.
CampochiaroPAHafizGChannaRAntagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology20101172387–94
38.
MatsumotoYFreundKBPeirettiECooneyMJFerraraDCYannuzziLARebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina200727426–31
39.
AchTHoehAESchaalKBScheuerleAFDithmarSPredictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol2010248155–9
40.
WroblewskiJJWellsJAIIIGonzalesCRPegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol2010149147–54
41.
BrownDMCampochiaroPASinghRPCRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology20101171124–33
42.
CampochiaroPAHeierJSFeinerLBRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology20101171102–12
43.
Salinas-AlamánAZarranz-VenturaJCaire González-JaureguiJMSádaba-EcharriLMBarrio-BarrioJGarcía-LayanaAIntravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol201121434–9
44.
OginoKTsujikawaAMurakamiTMuraokaYKurashigeYYoshimuraNGrid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. Clin Ophthalmol201151031–6
45.
WuLArevaloJFBerrocalMHComparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Retina2010301002–11
